Artificial intelligence has rapidly transformed the translation industry, particularly in life sciences, where documentation volumes are expanding and regulatory timelines are tightening. Life sciences organizations operate in a multilingual and highly regulated environment where precision is non-negotiable.
AI-powered translation technologies promise faster turnaround times, scalability, and cost efficiency. However, in life sciences, translation is a matter of patient safety, regulatory approval, and corporate accountability.
The responsible use of AI in life sciences translation means understanding one critical principle:
AI can accelerate workflows but it cannot replace human expertise.
Used incorrectly, AI introduces regulatory, ethical, and data security risks. Used responsibly, it becomes a powerful facilitator within a structured, human-led framework.
The Acceleration of Global Life Sciences and the Language Challenge
The life sciences sector is experiencing unprecedented growth. Pharmaceutical markets are expanding globally, clinical trials span continents, and medicinal products often require documentation in up to 26 official European Economic Area (EEA) languages.
At the same time:
- Regulatory timelines are shortening.
- Digital-first submissions are increasing.
- Patient-facing materials must be culturally adapted.
- Global collaboration is now the norm.
This creates immense pressure on translation processes.
Life sciences organizations manage vast volumes of:
- Clinical study reports
- Regulatory submissions
- Patient information leaflets
- Labeling and packaging documentation
- Post-marketing surveillance reports
In such an environment, even a minor linguistic error can:
- Delay product approvals
- Trigger regulatory rejection
- Cause legal complications
- Put patient safety at risk
This is precisely why AI must be carefully governed.
Where AI Adds Value in Life Sciences Translation
AI does bring meaningful benefits when implemented responsibly.
Speed and Scalability
Neural machine translation (NMT) systems can generate draft translations of large documents in minutes.
For example, a 50-page regulatory document can be processed far faster than through traditional manual workflows.
This acceleration supports:
- Faster time-to-market
- Rapid response to regulatory requests
- High-volume content processing
However, speed must not be mistaken for readiness. Draft output is not submission-ready output.
Terminology Consistency
AI systems integrated with Translation Memories (TMs) and Terminology Bases (TBs) can support consistency across multilingual documentation.
This is critical in life sciences, where:
- Regulated terminology must remain unchanged.
- Dose forms, routes of administration, and excipient information must align with official standards.
- Consistency across product dossiers is essential.
Yet terminology enforcement only works effectively within structured systems controlled by experts
Multilingual Collaboration
AI helps global teams:
- Translate internal communications
- Draft multilingual documentation
- Support cross-border collaboration
It can reduce communication barriers, enabling more efficient collaboration between research teams, regulatory departments, and global affiliates.
But collaboration support does not equal regulatory compliance.
The Hidden Risks of Relying Solely on AI in Regulated Environments
Despite its advantages, standalone AI translation presents serious risks in life sciences.
Accuracy Gaps Across Languages
AI systems are predominantly trained on English-centric data. Translation into English is generally more accurate than translation out of English, particularly into morphologically complex or digitally underrepresented languages.
This creates risk in multilingual regulatory environments, especially within the EEA, where documentation must be submitted in multiple official languages.
A translation that appears fluent may still contain subtle semantic inaccuracies.
Fluency does not guarantee correctness.
Regulatory Template Non-Compliance
Many life sciences documents must follow strict official templates, including:
- Summary of Product Characteristics (SmPCs)
- Patient Information Leaflets (PILs)
- Periodic Safety Update Reports (PSURs)
These documents require defined terms, a rigid structure that is not open to interpretation, complete and unalterable templates, and approved terminology.
Artificial intelligence operating without regulatory control systems may deviate from mandatory formats, even if it is linguistically correct.
Deviation in regulated areas means non-compliance.
Abbreviations, Lists, and Scientific Nuance
- Dense abbreviation usage (e.g., BRR, FP)
- Low-context bullet lists
- Domain-specific shorthand
It contains indirect procedural references.
AI systems frequently misinterpret these elements, particularly when context is limited.
Human subject matter experts understand procedural history, previous submissions, and product-specific nuance. AI does not.
Data Security and Confidentiality Risks in Public AI Tools
Life sciences documentation often contains:
- Proprietary research data
- Regulatory correspondence
- Strategic internal decisions
- Confidential safety findings
Public AI tools may:
- Temporarily store user-submitted data
- Use inputs for model training
- Operate on shared cloud infrastructure
In highly regulated industries, such risks are unacceptable.
This concern has already led many pharmaceutical organizations to restrict or ban the use of public generative AI tools in workplace environments.
Responsible AI use requires controlled, secure environments with strict data governance protocols.
ISO-Certified Human-Led Workflows: The Gold Standard
ISO 17100 mandates:
- Independent human translation
- Independent human revision
- Qualified linguists
- Documented quality assurance steps
Raw AI output with post-editing does not meet the full requirements of ISO 17100 for high-risk regulated content.
Instead, such workflows fall under ISO 18587 (post-editing of machine translation), which is not suitable for highly regulated submissions.
In life sciences, compliance is foundational.
AI+Human Workflows: The Responsible Model
The safest and most effective approach combines AI efficiency with human expertise.
Risk-Based Content Segmentation
Content should be categorized:
- High-risk: Regulatory submissions, patient labels → Full human oversight
- Lower-risk: Internal communications → Limited post-editing
Not all content requires the same level of intervention.
Controlled Terminology Ecosystems
Responsible AI use requires:
- Curated terminology databases
- Continuous glossary refinement
- Integration with translation memories
- SME validation
Terminology enforcement must be supervised by experts.
Structured Post-Editing Levels
Clear post-editing guidelines must define:
Light post-editing for low-risk materials
Full revision for high-risk documents
Post-editors must be trained to recognize typical AI output patterns and common errors.
Continuous Performance Monitoring
Responsible AI implementation is ongoing.
Organizations must monitor:
- Error rates
- Editing time
- Compliance deviations
- Inconsistencies in terminology
AI systems must be continuously refined within human-led governance structures.
The Future of Responsible AI in Life Sciences
The translation industry is moving beyond early AI hype toward a more realistic phase.
The future is not automation replacing humans. It is intelligent integration.
AI will:
- Improve productivity
- Support draft generation
- Assist terminology management
Humans will:
- Ensure semantic precision
- Ensure regulatory compliance
- Maintain accountability
- Protect patient safety
The role of human linguists is evolving.
How Mirora Ensures Responsible AI Integration
At Mirora, AI is positioned as a strategic enhancement to human expertise, never as a substitute for it. Our life sciences translation workflows are intentionally designed to remain human-led, with AI integrated only where it delivers clear operational benefits without compromising safety, accuracy, or compliance.
Every project begins with a structured evaluation process. We assess regulatory sensitivity, the potential impact on patient safety, the complexity of the language involved, and the level of data confidentiality required.
This risk-based assessment determines how AI can be responsibly incorporated into the workflow. If automation introduces even minimal unacceptable risk, human expertise takes precedence.
Our processes are built on strict terminology governance and controlled language assets to ensure consistency across all documents.
While AI contributes speed and scalability, our linguists, reviewers, and subject matter experts remain central to decision-making. They interpret clinical meaning, ensure regulatory alignment, and provide patient-facing clarity.
In our model, AI accelerates productivity but human professionals protect quality, compliance, and safety at every stage.
Comments are closed